• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction.

作者信息

Hillis W S, Hornung R S

出版信息

Eur Heart J. 1985 Nov;6(11):909-12. doi: 10.1093/oxfordjournals.eurheartj.a061787.

DOI:10.1093/oxfordjournals.eurheartj.a061787
PMID:3908105
Abstract
摘要

相似文献

1
The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction.BRL26921（茴香酰化纤溶酶原链激酶激活剂复合物）在急性心肌梗死中作为溶栓疗法的应用。
Eur Heart J. 1985 Nov;6(11):909-12. doi: 10.1093/oxfordjournals.eurheartj.a061787.
2
Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.急性心肌梗死患者静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或肝素后凝血与纤溶分析。一项比利时多中心研究。
Drugs. 1987;33 Suppl 3:253-60. doi: 10.2165/00003495-198700333-00047.
3
[Fibrinolysis therapy using APSAC in acute myocardial infarct].
Dtsch Med Wochenschr. 1990 Jun 22;115(25):999.
4
AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.目的。开展一项多中心死亡率研究，比较静脉注射安慰剂与30单位茴香酰化纤溶酶原链激酶激活剂复合物治疗病程小于6小时的急性心肌梗死的效果。英国茴香酰化纤溶酶原链激酶激活剂复合物咨询委员会。
Drugs. 1987;33 Suppl 3:227-8. doi: 10.2165/00003495-198700333-00040.
5
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.
6
Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.第二代溶栓剂茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）的研发与评估。
J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):22B-27B. doi: 10.1016/s0735-1097(87)80424-2.
7
Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.茴香酰化纤溶酶原链激酶激活剂复合物与安慰剂对比：急性心肌梗死安全性及早期死亡率的初步多中心研究
Drugs. 1987;33 Suppl 3:261-7. doi: 10.2165/00003495-198700333-00048.
8
Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.茴香酰化纤溶酶原链激酶激活剂复合物和链激酶治疗急性心肌梗死的全身效应。荷兰侵入性再灌注研究的凝血方面。
Drugs. 1987;33 Suppl 3:242-6. doi: 10.2165/00003495-198700333-00045.
9
Should we intervene following thrombolytic therapy? The SWIFT study in progress. UK APSAC Advisory Committee.溶栓治疗后我们是否应进行干预？正在进行的SWIFT研究。英国APSAC咨询委员会。
Drugs. 1987;33 Suppl 3:229-30. doi: 10.2165/00003495-198700333-00041.
10
A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction.一项关于静脉注射30U茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死的安慰剂对照通畅性研究。
Drugs. 1987;33 Suppl 3:138-9. doi: 10.2165/00003495-198700333-00022.

引用本文的文献

1
Drug utilisation review and pharmacoeconomics: interaction after parallel development?药物利用评价与药物经济学：平行发展后的相互作用？
Pharmacoeconomics. 1993 Sep;4(3):162-72. doi: 10.2165/00019053-199304030-00002.
2
Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死的生物学研究
Drugs. 1987;33 Suppl 3:268-74. doi: 10.2165/00003495-198700333-00049.
3
Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
急性心肌梗死患者中两种静脉溶栓药物（茴香酰化纤溶酶原链激酶激活剂复合物与链激酶）的评估。
Drugs. 1987;33 Suppl 3:169-74. doi: 10.2165/00003495-198700333-00028.
4
Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.急性心肌梗死再灌注治疗。美国一项关于早期冠状动脉内注射链激酶与静脉注射茴香酰化纤溶酶原链激酶激活剂复合物的多中心随机试验。
Drugs. 1987;33 Suppl 3:154-62. doi: 10.2165/00003495-198700333-00026.
5
A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusions.一项关于异烟酰化纤溶酶原链激酶激活剂复合物治疗急性冠状动脉闭塞的随机安慰剂对照剂量反应试验性研究。
Drugs. 1987;33 Suppl 3:133-7. doi: 10.2165/00003495-198700333-00021.
6
Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）。对其作用机制、临床药理学及在急性心肌梗死中的治疗应用的综述。
Drugs. 1987 Jul;34(1):25-49. doi: 10.2165/00003495-198734010-00002.
7
Thrombolytic treatment and new calcium antagonists.溶栓治疗与新型钙拮抗剂。
Br Med J (Clin Res Ed). 1988 Mar 5;296(6623):705-8. doi: 10.1136/bmj.296.6623.705.
8
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.